These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23827659)

  • 1. Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.
    Rebolj M; Preisler S; Ejegod DM; Bonde J; Rygaard C; Lynge E
    J Mol Diagn; 2013 Sep; 15(5):670-7. PubMed ID: 23827659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
    Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
    J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.
    Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL
    Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
    Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
    J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
    Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
    J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
    Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
    BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
    Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
    Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
    Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
    J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
    Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
    Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
    Jentschke M; Soergel P; Hillemanns P
    J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
    Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
    J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.
    Dockter J; Schroder A; Hill C; Guzenski L; Monsonego J; Giachetti C
    J Clin Virol; 2009 Jul; 45 Suppl 1():S55-61. PubMed ID: 19651370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical performance of RNA isolated from BD SurePath™ cervical cytology specimens by the PreTect™ HPV-Proofer assay.
    Dixon EP; Grønn P; King LM; Passineau H; Doobay H; Skomedal H; Hariri J; Hay SN; Brown CA; Fischer TJ; Malinowski DP
    J Virol Methods; 2012 Nov; 185(2):199-203. PubMed ID: 22820075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4.
    Cuzick J; Ahmad AS; Austin J; Cadman L; Ho L; Terry G; Kleeman M; Ashdown-Barr L; Lyons D; Stoler M; Szarewski A
    J Clin Virol; 2016 Sep; 82():145-151. PubMed ID: 27498250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing of integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care?
    Sauter JL; Mount SL; St John TL; Wojewoda CM; Bryant RJ; Leiman G
    Acta Cytol; 2014; 58(2):162-6. PubMed ID: 24526177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.
    Ejegod DM; Rebolj M; Bonde J
    BMC Cancer; 2015 Apr; 15():216. PubMed ID: 25886410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay.
    Halfon P; Benmoura D; Agostini A; Khiri H; Martineau A; Penaranda G; Blanc B
    J Clin Virol; 2010 Feb; 47(2):177-81. PubMed ID: 20022804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women.
    Nielsen A; Iftner T; Nørgaard M; Munk C; Junge J; Kjaer SK
    Sex Transm Infect; 2012 Dec; 88(8):627-32. PubMed ID: 22773328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.